Key result
Conservative management with bridging therapies such as nutritional support or botulinum toxin injection is recommended for achalasia during pregnancy, with definitive treatment deferred until after delivery.
Why the study?
Achalasia in pregnancy is rare and poses diagnostic and therapeutic challenges, but no management guidelines exist.
A proposed management algorithm for achalasia during pregnancy recommends conservative bridging therapies to ensure adequate nutrition until definitive postpartum treatment.
Management of achalasia in pregnancy lacks guidelines amid diagnostic challenges; leaves open evidence-based recommendations pending further data.
Fewer than 40 cases of achalasia occurring in pregnant woman have been reported in the literature. Given the rarity of achalasia during pregnancy, and the numerous treatment options that are available for achalasia in general, no guidelines exist for the management of achalasia during pregnancy. Diagnosis of new cases may be difficult as symptoms and physiological changes that occur during pregnancy may obscure the clinical presentation of achalasia. The management of achalasia in pregnancy is also challenging. Treatment decisions should be individualized for each case, considering both the welfare of the mother and the fetus. Since pregnant women suffering from achalasia represent a diagnostic and therapeutic challenge with complex maternal-fetal aspects to consider, we have reviewed the available literature on the subject and summarized current diagnostic and therapeutic options. Additionally, we present a management algorithm as a means to guide treatment of future cases. We recommend that a conservative approach should be adopted with bridging therapies performed until after delivery when definitive treatment of achalasia can be more safely performed.
No takes yet. Share an insight, caveat, or question.
Vosko et al. (2020) conducted a review in Achalasia during pregnancy. Bridging therapies (nasogastric tube, parenteral nutrition, botulinum toxin injection, pneumatic dilation) was evaluated. Conservative management with bridging therapies such as nutritional support or botulinum toxin injection is recommended for achalasia during pregnancy, with definitive treatment deferred until after delivery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: